NeuroMetrix EBITDA Margin from 2010 to 2024
| NURO Stock | USD 4.33 0.68 18.63% |
Check NeuroMetrix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroMetrix main balance sheet or income statement drivers, such as Depreciation And Amortization of 52.9 K, Interest Expense of 278 K or Total Revenue of 5.6 M, as well as many exotic indicators such as Price To Sales Ratio of 0.6, Dividend Yield of 21.96 or PTB Ratio of 0.18. NeuroMetrix financial statements analysis is a perfect complement when working with NeuroMetrix Valuation or Volatility modules.
NeuroMetrix | EBITDA Margin |
About NeuroMetrix Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include NeuroMetrix income statement, its balance sheet, and the statement of cash flows. NeuroMetrix investors use historical funamental indicators, such as NeuroMetrix's EBITDA Margin, to determine how well the company is positioned to perform in the future. Although NeuroMetrix investors may use each financial statement separately, they are all related. The changes in NeuroMetrix's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on NeuroMetrix's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on NeuroMetrix Financial Statements. Understanding these patterns can help to make the right decision on long term investment in NeuroMetrix. Please read more on our technical analysis and fundamental analysis pages.
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts. Neurometrix operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 23 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of NeuroMetrix Correlation against competitors. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for NeuroMetrix Stock analysis
When running NeuroMetrix's price analysis, check to measure NeuroMetrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroMetrix is operating at the current time. Most of NeuroMetrix's value examination focuses on studying past and present price action to predict the probability of NeuroMetrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroMetrix's price. Additionally, you may evaluate how the addition of NeuroMetrix to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is NeuroMetrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.27) | Revenue Per Share 5.664 | Quarterly Revenue Growth (0.29) | Return On Assets (0.19) | Return On Equity (0.30) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.